Epitome Therapeutics Raises €4 Mn in Pre-Seed Round

The funding includes an oversubscribed €2 million pre-seed investment round and €2 million in non-dilutive grant funding.

Read Also- Lucida AI Raises €6.1 Mn in Seed Round led by Velocity Capital

The pre-seed round was co-led by XISTA Science Ventures and Caesar Ventures, with additional investment from Navec Venture Holding GmbH.

“We are launching Epitome Therapeutics with the support of a strong group of investors and partners,” said Dr. Guido Gualdoni, Co-Founder and CEO of Epitome Therapeutics. “Completing an oversubscribed financing is a strong endorsement of both our team and the potential of the CADENCE platform. The new funding enables us to build the company around CADENCE and translate our science into the first development programmes. Our immediate focus is to advance the platform, expand our team, and work toward the selection of our first drug candidate.”

“Genes do not simply need to be ON or OFF – they need to be expressed at the right level,” said Dr. Jamie Hackett, Co-Founder and CSO of Epitome Therapeutics. “Many diseases arise when that balance is disrupted. The CADENCE platform enables precise control of gene dosage, allowing us to restore activity of specific genes to therapeutically meaningful levels. We believe this precision medicine approach represents a fundamentally new therapeutic modality to treat genetic and complex disease”

Alexander Schwartz, Partner at XISTA Science Ventures, commented: “We were impressed by the breakthrough nature of Epitome Therapeutics’ approach to epigenome editing, especially its focus on targeted upregulation, and by the team’s ambition to translate this science into therapeutically relevant programmes. We are delighted to be amongst the first to support the company as it achieves the first development milestones and as the field continues to gain momentum.”

“With our investment in Epitome Therapeutics, we are backing an exceptional team that has rethought gene regulation. What convinced us is the rare combination of scientific depth and entrepreneurial experience around Guido and Jamie. We are delighted to support the team as an investor in their first major financing round,” added Gregor Unger, Managing Partner at Caesar Ventures.

Founded in 2025 by Dr. Gualdoni and Dr. Jamie Hackett, Epitome Therapeutics is developing CADENCE, a next-generation epigenome editing platform that helps control how genes are turned on or off without changing the DNA itself.

The company aims to use this technology to develop new treatments for diseases caused by abnormal gene activity, including rare diseases and metabolic disorders.